Longeveron (NASDAQ:LGVN – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.
Risk and Volatility
Longeveron has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Insider and Institutional Ownership
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 11.2% of Longeveron shares are owned by company insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,893.58% | -199.79% | -143.21% |
| Voyager Therapeutics | -296.53% | -51.35% | -39.38% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Longeveron and Voyager Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 0 | 1 | 0 | 2.00 |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Longeveron currently has a consensus target price of $3.00, indicating a potential upside of 167.86%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 329.69%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Longeveron.
Earnings and Valuation
This table compares Longeveron and Voyager Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 21.72 | -$22.70 million | ($1.28) | -0.88 |
| Voyager Therapeutics | $40.37 million | 5.67 | -$119.72 million | ($2.03) | -1.89 |
Longeveron has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats Longeveron on 10 of the 15 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
